![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 16, 2016 9:55:15 PM
I'd believe that the delay in releasing the 10Q is likely all about how the footnote will read in regard to the FDA regulations. Given the action of the stock recently, I'd guess that the not-so-great financial results and the uncertain to negative regulatory environment have already been factored into the stock price, but it's really hard to keep an analytical frame of mind when the stock seems to bounce all over the place from trade to trade.
Overall, I think that this company is ripe for sale, as the products seem to be leading edge but the finances are holding the company back from fully capitalizing on its competitive advantages.
Maybe I'll add to this when the 10Q appears, but these are the moments when I miss folks like Sgreg on this board who are better at analysis than I am.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM